These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21651481)

  • 21. Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth.
    Pérez-Pérez MJ; Priego EM; Bueno O; Martins MS; Canela MD; Liekens S
    J Med Chem; 2016 Oct; 59(19):8685-8711. PubMed ID: 27348355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 3-(3,4,5-Trimethoxyphenylselenyl)-1H-indoles and their selenoxides as combretastatin A-4 analogs: microwave-assisted synthesis and biological evaluation.
    Wen Z; Xu J; Wang Z; Qi H; Xu Q; Bai Z; Zhang Q; Bao K; Wu Y; Zhang W
    Eur J Med Chem; 2015 Jan; 90():184-94. PubMed ID: 25461319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combretastatin-based compounds with therapeutic characteristics: a patent review.
    Nainwal LM; Alam MM; Shaquiquzzaman M; Marella A; Kamal A
    Expert Opin Ther Pat; 2019 Sep; 29(9):703-731. PubMed ID: 31369715
    [No Abstract]   [Full Text] [Related]  

  • 24. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
    Dark GG; Hill SA; Prise VE; Tozer GM; Pettit GR; Chaplin DJ
    Cancer Res; 1997 May; 57(10):1829-34. PubMed ID: 9157969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum.
    Pettit GR; Singh SB; Niven ML; Hamel E; Schmidt JM
    J Nat Prod; 1987; 50(1):119-31. PubMed ID: 3598594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
    Cushman M; Nagarathnam D; Gopal D; Chakraborti AK; Lin CM; Hamel E
    J Med Chem; 1991 Aug; 34(8):2579-88. PubMed ID: 1875350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Use of Stilbene Scaffold in Medicinal Chemistry and Multi- Target Drug Design.
    Giacomini E; Rupiani S; Guidotti L; Recanatini M; Roberti M
    Curr Med Chem; 2016; 23(23):2439-89. PubMed ID: 27183980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds.
    Cooney MM; Ortiz J; Bukowski RM; Remick SC
    Curr Oncol Rep; 2005 Mar; 7(2):90-5. PubMed ID: 15717941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4.
    Griggs J; Skepper JN; Smith GA; Brindle KM; Metcalfe JC; Hesketh R
    Am J Pathol; 2002 Mar; 160(3):1097-103. PubMed ID: 11891206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of novel 1-indolyl acetate-5-nitroimidazole derivatives of combretastatin A-4 as potential tubulin polymerization inhibitors.
    Yao YF; Wang ZC; Wu SY; Li QF; Yu C; Liang XY; Lv PC; Duan YT; Zhu HL
    Biochem Pharmacol; 2017 Aug; 137():10-28. PubMed ID: 28456516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CA-1H, a novel oxazole bearing analogue of combretastatin A-4, disrupts the tumor vasculatures and inhibits the tumor growth via inhibiting tubulin polymerization.
    Han F; Wang P; Zhang W; Li J; Zhang Q; Qi X; Liu M
    Biomed Pharmacother; 2016 May; 80():151-161. PubMed ID: 27133052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and biological evaluation of cyclic derivatives of combretastatin A-4 containing group 14 elements.
    Blasco V; Murga J; Falomir E; Carda M; Royo S; Cuñat AC; Sanz-Cervera JF; Marco JA
    Org Biomol Chem; 2018 Aug; 16(32):5859-5870. PubMed ID: 30070286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lead identification of conformationally restricted benzoxepin type combretastatin analogs: synthesis, antiproliferative activity, and tubulin effects.
    Barrett I; Carr M; O'Boyle N; Greene LM; Knox AJ; Lloyd DG; Zisterer DM; Meegan MJ
    J Enzyme Inhib Med Chem; 2010 Apr; 25(2):180-94. PubMed ID: 20222762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sydnone Cycloaddition Route to Pyrazole-Based Analogs of Combretastatin A4.
    Brown AW; Fisher M; Tozer GM; Kanthou C; Harrity JP
    J Med Chem; 2016 Oct; 59(20):9473-9488. PubMed ID: 27690431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vascular disrupting agents in clinical development.
    Hinnen P; Eskens FA
    Br J Cancer; 2007 Apr; 96(8):1159-65. PubMed ID: 17375046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments.
    Ji YT; Liu YN; Liu ZP
    Curr Med Chem; 2015; 22(11):1348-60. PubMed ID: 25620094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hybrid
    Piekuś-Słomka N; Mikstacka R; Ronowicz J; Sobiak S
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin.
    Lin CM; Ho HH; Pettit GR; Hamel E
    Biochemistry; 1989 Aug; 28(17):6984-91. PubMed ID: 2819042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combretastatins: from natural products to drug discovery.
    Cirla A; Mann J
    Nat Prod Rep; 2003 Dec; 20(6):558-64. PubMed ID: 14700199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub).
    el-Zayat AA; Degen D; Drabek S; Clark GM; Pettit GR; Von Hoff DD
    Anticancer Drugs; 1993 Feb; 4(1):19-25. PubMed ID: 8457709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.